Sunday, March 17, 2024 10:46:33 PM
Just set a sell limit for $6.00 and forget it.
Ok lets be realistic set a sell limit for 6 cents like the 3 year high was .0617
You know for a fact I did not say RS!
That was in reply to your thinking RSPI was going to .0006 so I countered your reply in the other direction.
Can you imagine how much a short could lose if it went to 6 cents or even crazier $6 LOL
Another crazy thing is lets just say you let it run to 6 cents or $6 and the shorts could have fun all over again.
You don't know that RSPI will go down to .0006 and I don't know if RSPI will ever go to 6 cents or $6
I do know RSPI will go up and it will go down in fluctuation.
I guess you are a RSPI buyer @ .0006 or others will cover at .0006 if they are short.
Pharmaceutical stocks go crazy in both directions you know that.
Revolutionary KRM-II-81 New Hope:
KRM-II-81 Drug-Resistant Epilepsy Patients
https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/
National Institutes of Health
A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/
Jodi L. Smith, PhD, MD, FAANS, Director, Pediatric Neurosurgery at Peyton Manning Children’s Hospital at Ascension St. Vincent Medical in Indianapolis, IN led this research effort and is quoted as saying, “I am happy to report that a year after the surgery the patient is seizure-free but remains on seizure medication. Although our research team has observed suppression of activity previously in cortical tissue from epileptic patients, we have now observed recurrent epileptiform bursting in this patient’s tissue. KRM-II-81 fully suppressed the epileptiform bursting, which returned when KRM-II-81 was removed from the incubation medium. We feel that this observation is an impressive indicator for success in translation to patient treatment for this compound.”
Jodi L. Smith, MD, is a pediatric neurosurgeon at Peyton Manning Children's Hospital at Ascension St. Vincent Pediatric Neurosurgery in Indianapolis, Indiana.
Dr. Jodi L. Smith is an academic pediatric neurosurgeon at James Whitcomb Riley Hospital for Children and an Associate Professor of Neurological Surgery in the Department of Neurological Surgery at the Indiana University Medical Center/Indiana University School of Medicine in Indianapolis, Indiana.
Dr. Smith received her Ph.D. in Anatomy at the University of Utah School of Medicine for her doctoral dissertation studies on "Neurulation." Dr. Smith subsequently completed medical school and residency training in Neurological Surgery at the University of Utah, as well. Following residency, Dr. Smith completed a pediatric neurosurgery fellowship at Children's Hospital, Harvard Medical School in Boston, Massachussetts. Dr. Smith joined the Department of Neurological Surgery at the Indiana University Medical Center/Indiana University School of Medicine in Indianapolis, Indiana in 2000.
Dr. Smith is a Diplomat of the American Board of Neurological Surgery, and her memberships include The Congress of Neurological Surgeons, The American Association of Neurological Surgeons, The American Association of Neurological Surgeons - Pediatric Section, and The Society for Neuroscience.
Dr. Smith is the founder and Co-director of the pediatric surgical epilepsy program at Riley Hospital for Children, Indiana University School of Medicine. Her responsibilities include (1) evaluating pediatric patients with medically refractory epilepsy to determine whether they qualify for surgical treatment of their seizures; and (2) operating on all children with medically refractory epilepsy who are found to be appropriate surgical candidates in order to rid them of their debilitating seizures.
Specialties: Dr. Smith's clinical interests include pediatric epilepsy surgery, brain and spinal cord tumors, brain and spinal cord congenital malformations, hydrocephalus, myelodsyplasia, craniofacial disorders, and Moyamoya syndrome. Dr. Smith's research interests include understanding the cellular and molecular mechanisms of neurulation and understanding the electrophysiological properties of dysplastic/epileptogenic human cortical tissue using a multi channel electrode array.
The manuscript’s corresponding author Rok Cerne, MD, PhD, Senior Research Fellow with RepireRx, said that “the bursting activity across a neural network is a unique signature of epilepsy that we were able to observe in the cortical tissue from this patient. Prior to surgery, this 19-year-old patient suffered from seizures in the presence of multiple standard anti-seizure medications. The complete abolishment of these epileptic bursts by our GABAkine is one of most impressive demonstrations we have made to date with KRM-II-81. The data are highly encouraging for us to continue with IND enabling animal studies conducted in collaboration with the National Institutes of Health and to move into the clinic with KRM-II-81.”
https://www.otcmarkets.com/stock/RSPI/news/story?e&id=2731514
Rok Cerne, MD, PhD, Senior Research Fellow with RepireRx
Rok Cerne. Principal Research Scientist at Eli Lilly and Company. Eli Lilly and Company Iowa State University. Indianapolis, Indiana, United States.
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
ResolutionRx: Pharmaceutical Cannabinoids.
ResolutionRx Ltd (Australian Company Number a/k/a ACN 664 925 651) was formed in Australia on January 11, 2023 by RespireRx as an unlisted public company. RespireRx has contributed by sublicense and license with ResolutionRx, its sleep apnea drug development program subject to certain liabilities. ResolutionRx now engages in the research and development (“R&D”) associated with that program, initially for the development of a new formulation of dronabinol for use in a Phase 3 clinical trial and the filing for regulatory approval for the treatment of obstructive sleep apnea (“OSA”). The current total budget for that program over the next several years is approximately US$16.5 million, most, but not all of which is expected to be eligible for the Australian R&D Tax Incentive (“RDTI”). Dronabinol, an endocannabinoid receptor agonist, has already demonstrated significant improvement in the symptoms of OSA in two Phase 2 clinical trials. OSA is a serious respiratory disorder that impacts an estimated 90 million people in the United States, the United Kingdom, Germany and Australia and that has been linked to increased risk for hypertension, heart failure, depression, and diabetes. There are no approved drug treatments for OSA.
Because dronabinol is already FDA approved for the treatment of AIDS related anorexia and chemotherapy induced nausea and vomiting, RespireRx and ResolutionRx further believe that its repurposing strategy would only require, in the United States, approval by the FDA of a 505(b)(2) new drug application (“NDA”), an efficient regulatory pathway that allows the use of publicly available data.
on January 18, 2024, the Board of Directors of RespireRx Pharmaceuticals Inc. appointed a new director, Dariusz Nasiek to the Board who is considered to be an outside director.
Dr. Nasiek, MD, MBA, is a dedicated anesthesiologist with expertise in anesthesiology and interventional pain management. Dr. Nasiek is board certified by the American Board of Anesthesiology, the American Board of Pain Medicine and the American Board of Interventional Pain Physicians. Dr. Nasiek is also a Life Member of the American Society of Interventional Pain Physicians and a Member of the International Spine Intervention Society. He has been a practicing physician for the last 35 years. Since 2006, he has been the Managing Partner of Allied Neurology & Interventional Pain Practice, and since 2008, he has served as the Director of Anesthesiology at Hackensack Surgery Center. Dr. Nasiek is a leader specializing in non-surgical options for the treatment of spinal and non-spinal pain and is a pioneer in the use of innovative techniques in the cervical, thoracic and lumbar spine. His forward-looking approaches to pain management, regenerative medicine and tissue healing are described in the new 2nd Edition of his book entitled, “PRP, Platelet Rich Plasma: A New Paradigm in Regenerative Medicine.”
RespireRX Gabakine KRM-II-81
KRM-II-81 is the lead compound in a new series of orally bioavailable imidazodiazepines entering IND-enabling safety studies.
KRM-II-81 has a preclinical profile predicting efficacy against pharmacoresistant epilepsies, traumatic brain injury, and neuropathic pain.
KRM-II-81 is the most advanced and druggable of a series of compounds that display certain receptor subtype selectivity and pharmacological specificity. In studies using cell cultures, brain tissues and whole animals, KRM-II-81 acts as a GABAA PAM at selective GABAA receptor subtypes that we feel are intimately involved in neuronal processes underlying epilepsy, pain, anxiety and certain other indications.
KRM-II-81 has demonstrated highly desirable properties in animal models of these and other potential therapeutic indications, in the absence of or with greatly reduced liability to produce sedation, motor incoordination, cognitive impairments, respiratory depression, tolerance, abuse and withdrawal seizures, all side effects associated with BDZs. We currently are focused on the potential treatment of epilepsy and pain.
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.sciencedirect.com/science/article/pii/S2405844023109601
Dampening effects of KRM–II–81 on epileptiform bursting in a slice of left temporal lobe focal brain tissue resected from the patient. Data were collected for 1 h under control conditions (Control), in the presence of 30 µM KRM–II–81 (KRM–II–81 (30 µM)), and after the wash out of KRM–II–81 (Wash).
B. Summary data for the epileptiform burst activity under 1 h control, KRM–II–81, and wash out conditions. KRM–II–81 completely suppressed epileptic bursting activity in the slice.
KRM-II-81 is an imidazodiazepine anticonvulsant that has shown promising results in preclinical studies. Here are some key findings:
• KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment-resistant and pharmaco-resistant models.
• It has been effective across a broad array of anti-seizure models including those predicting efficacy in patients that are pharmaco-resistant and in brain tissue from epilepsy patients who are no longer treatable with drugs.
• Notably, KRM-II-81 was found to be highly effective in these models, and pharmaco-resistance or tolerance did not develop to its anti-convulsant properties.
• In addition to its anti-convulsant properties, KRM-II-81 has also shown to be effective in relieving acute, chronic, and neuropathic pain in a number of models without developing tolerance or producing sedation.
• KRM-II-81 has also displayed a high degree of analgesic activity in a broad range of preclinical studies.
These results suggest that KRM-II-81 could potentially be a promising candidate for the treatment of epilepsy and chronic pain.
KRM-II-81 has shown some promising results when compared to other anticonvulsants. Here are some key points:
• KRM-II-81 is more potent and generally more efficacious than standard-of-care antiepileptics.
• In multiple chemical seizure provocation models in mice, KRM-II-81 was either equally or more efficacious than that of Diazepam (DZP). Most strikingly, KRM-II-81 but not DZP blocked the development of seizure sensitivity to the chemical convulsants cocaine and pentylenetetrazol.
• KRM-II-81 produces broad-based anticonvulsant and antinociceptive efficacy in rodent models and provides a wider margin over motoric side effects than that of other GABAA receptor PAMs
KRM-II-81 has been studied in preclinical trials and so far, it has not displayed side effects such as sedation and motor impairment.
Importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability.
However, these are preclinical findings, and further research, including clinical trials in humans, would be necessary to fully understand its safety profile. Always consult with a healthcare professional before starting any new medication.
The global epilepsy drug market size varies according to different sources:
• According to Mordor Intelligence, the epilepsy drugs market is projected to register a CAGR of 3.5% during the forecast period.
• Grand View Research reported that the global epilepsy drugs market size was valued at USD 10.15 billion in 2022 and is expected to grow at a CAGR of 5.1% from 2023 to 2030.
• Allied Market Research valued the global epilepsy drugs market size at $7 billion in 2022, and projected it to reach $9.8 billion by 2032, growing at a CAGR of 3.5% from 2023 to 2032.
• Fortune Business Insights reported that the global antiepileptic drugs (AED) market size was valued at USD 15.55 billion in 2022, and is projected to grow from USD 16.50 billion in 2023 to USD 22.37 billion by 2030, exhibiting a CAGR of 4.4% during the forecast period.
• The Brainy Insights reported that the global epilepsy drugs market was valued at USD 10 billion in 2022 and grew at a CAGR of 4% from 2023 to 2032. The market is expected to reach USD 14.80 billion by 2032.
RespireRX has been accepted into the NIH HEAL Initiative® NINDS Preclinical Screening Platform for Pain (PSPP) program. The company’s lead GABAkine, KRM-II-81, is being developed because of its ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects.
On August 3, 2023, RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd, its wholly-owned, unlisted, public Australian subsidiary entered into a License Agreement pursuant to which, RespireRx has licensed to ResolutionRx, the Intellectual Property which includes the Patent Rights. The License is an exclusive, worldwide and royalty-free license during the Term to use and exploit the Licensed IP in connection with ResolutionRx’s business and operations, including commercial and non-commercial purposes, with the exception that RespireRx shall have the exclusive right to use the technology described in the Licensed IP for non-cannabinoid products. ResolutionRx shall use its best efforts to commercialize the Licensed IP.
The Licensed IP is basically, the intellectual property and patent rights, and associated with the new dronabinol formulation initially to be developed for the treatment of obstructive sleep apnea.
On October 9, 2023, ResolutionRx Ltd a wholly owned Australian, public, unlisted subsidiary of RespireRx Pharmaceuticals Inc. entered into a Master Services Agreement with Ab Initio Pharma Pty Ltd, an Australian company for Ab Initio to manufacture, formulate, test and supply ResolutionRx with therapeutic drugs based on lipid nanoparticle technology licensed from RespireRx to ResolutionRx.
The initial services relate to ResolutionRx’s repurposing of dronabinol and its development program for obstructive sleep apnea pursuant to which Ab Initio will, among other things, manufacture and test our new dronabinol lipid nanoparticle formulation for pharmacokinetic, pharmacodynamic, and pivotal clinical trials as well as ultimately for commercialization.
On December 6, 2023, RespireRx Pharmaceuticals Inc. entered into an agreement with Ponto Ventures LLC, pursuant to which Ponto will provide the services of Will Clodfelter. Clodfelter will be retained by the Company as our Senior Vice President of Business Development. Also on December 6, 2023, the Company entered into an agreement with Seven Life Sciences related to the introduction of Ponto and Consultant to the Company.
Consulting Agreement
Pursuant to the terms of the Consulting Agreement, the parties agreed that Clodfelter will be retained by the Company as the Senior Vice President of Business Development through Ponto on a part-time basis.
Consultant’s duties will be such duties as are normally associated with the position of Senior Vice President of Business Development, working as an independent contractor and not as an employee, with an initial focus on the programs of ResolutionRx Ltd, the Company’s wholly-owned Australian subsidiary. Consultant will collaborate with Jeff Eliot Margolis, the Company’s Senior Vice President, Chief Financial Officer, Treasurer and Secretary and together, both will periodically submit the results of their efforts to Dr. Arnold Lippa, the Interim Chief Executive Officer, Interim President and Chief Scientific Officer of the Company.
Consultant will in all ways, satisfy the requirements of being an independent contractor.
In the event Clodfelter is involved in any substantive way in the successful consummation of a strategic transaction resulting in cash proceeds to the Company or one of its subsidiaries, the Company on behalf of itself or the appropriate subsidiary shall create a success bonus pool calculated on a tiered formula calculated on all funds, in the aggregate, received with respect to such transaction, upfront or in milestone payments once received. For clarity, royalties, profit participation or similar funds received will not be funds utilized in the calculation of the bonus. Since all funds may not be received at one time, to determine the “tier” the funds that are received shall be aggregated with funds previously received.
Dronabinol is marketed as Marinol and Syndros, a registered trademark of Solvay Pharmaceuticals.
Dronabinol is also marketed, sold, and distributed by PAR Pharmaceutical Companies under the terms of a license and distribution agreement with SVC pharma LP, an affiliate of Rhodes Technologies for Marinol and Insys Pharmaceuticals for Syndros.
RespireRx
RespireRx is developing a pipeline of new drug products based on our broad patent portfolios for two drug platforms, including dronabinol (D-9THC), and the ampakines, which positively modulate AMPA-type glutamate receptors to promote neuronal function.
RespireRx holds the exclusive world-wide license to a broad family of patents for the use of cannabinoids in the treatment of sleep related breathing disorders from the University of Illinois at Chicago (UIC). There are six issued patents, and we have several extensions and pending applications that will extend patent protection for over a decade.
Under the terms of the license agreement, RespireRx now holds the exclusive rights to develop and commercialize dronabinol for sleep related breathing disorders. The use of dronabinol for the treatment of OSA is a new indication for an already approved drug, thereby allowing RespireRx or a development partner to submit a 505(b)2 application to FDA for approval of a new dronabinol label. This regulatory path may offer market protections under HatchWaxman provisions for market exclusivity at FDA. Other regulatory routes are available to pursue proprietary formulations of dronabinol that will provide further market protections.
Obstructive sleep apnea syndrome (OSA) is a sleep-related breathing disorder that afflicts an estimated 29 million people in the United States and over 100 million people worldwide.
Average cost to treat a patient with OSA is approximately $2,100 per year.
Dronabinol is a Schedule III, controlled generic drug that has been approved by the U.S. FDA for the treatment of AIDS-related anorexia and chemotherapy-induced emesis. Dronabinol is available in the United States as the branded prescription drug product Marinol® capsules. Marinol®, together with numerous generic formulations, is available in 2.5, 5, and 10 mg capsules, with a maximum labelled dosage of 20 mg/day for the AIDS indication, or 15 mg/m2 per dose for chemotherapy-induced emesis.
Marinol
What is the cost of Marinol
Marinol prices
Oral Capsule
2.5 mgMarinol oral capsule
from $740.72for 60 capsules
5 mgMarinol oral capsule
from $1,531.40for 60 capsules
The cost for Marinol oral capsule 2.5 mg is around $741 for a supply of 60 capsules, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
A generic version of Marinol is available. See dronabinol prices (from $94.16 for 60 capsules).
Syndros
Syndros (dronabinol) is a member of the miscellaneous antiemetics drug class and is commonly used for AIDS Related Wasting, Anorexia, and Nausea/Vomiting - Chemotherapy Induced.
The cost for Syndros oral solution (5 mg/mL) is around $1,227 for a supply of 30 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
https://www.pharmacychecker.com/syndros/#!
Syndros is available as a brand name drug only, a generic version is not yet available.
RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development
Mr. Clodfelter will initially lead the business development efforts with respect to dronabinol, the lead asset of ResolutionRx Ltd, a wholly-owned Australian subsidiary of the Company. Mr. Clodfelter will collaborate with Jeff Eliot Margolis, the Company’s Senior Vice President
Mr. Clodfelter has extensive experience providing business development, strategy, and valuation consulting services to pharmaceutical, biotech and medical device companies, where he has led or been a core member on over 30 international and domestic pharmaceutical licensing and device negotiations ranging from preclinical to launched products. This experience extends across large pharmaceutical, biotechnology and medical device companies. He previously held positions at Eli Lilly and Co. in Corporate Strategy and Business Development. He was at Amylin Pharmaceuticals in New Product Planning and Decision Sciences and was involved in multiple business development activities. Following Amylin, Mr. Clodfelter was the Chief Executive Officer of Medicus Biosciences and Abvance Therapeutics, both biotechnology firms based in California.
Will Clodfelter
Managing DirectorManaging Director
Ponto Ventures, LLC
Linkedin 4,028 followers
Business Development | Biotech Leadership and Startup | Corporate Strategy | Medical Devices | Pharmaceuticals | CEO | CBO
Biotech executive with extensive experience in developing and implementing corporate strategy, managing complex relationships and cross-cultural teams, and monetizing ideas for startup biotech ventures. Recognized for ability to distill complex scientific and engineering principles and translate into actionable, market-based business strategies. Managed P&L for startup and established firms. Core member on over 30 international and domestic licensing and device negotiations ranging from pre-clinical to launched products.
Key strengths include: business development, corporate and asset strategy, device development, alliance management, negotiations, licensing, financial valuations, forecasting, market research, new product planning
$RSPI
KRM-II-81 New Hope
https://investorshub.advfn.com/uimage/uploads/2024/2/9/fmidjKRM1.jpg
Drug Companies making Epilepsy medication
MRNS $10.08
CERE $43.16
STOK $4.98
UCBJF $102.00
SNY $45.63
PFE $27.00
OTSUK $18.36
RespireRx Pharmaceuticals Ticker: RSPI
Is working on Revolutionary New Hope:
KRM-II-81 Drug-Resistant Epilepsy Patients
Link found on National Library of Medicine
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders
https://pubmed.ncbi.nlm.nih.gov/35041859/
https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/
National Institutes of Health
A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/
Ok lets be realistic set a sell limit for 6 cents like the 3 year high was .0617
You know for a fact I did not say RS!
That was in reply to your thinking RSPI was going to .0006 so I countered your reply in the other direction.
Can you imagine how much a short could lose if it went to 6 cents or even crazier $6 LOL
Another crazy thing is lets just say you let it run to 6 cents or $6 and the shorts could have fun all over again.
You don't know that RSPI will go down to .0006 and I don't know if RSPI will ever go to 6 cents or $6
I do know RSPI will go up and it will go down in fluctuation.
I guess you are a RSPI buyer @ .0006 or others will cover at .0006 if they are short.
Pharmaceutical stocks go crazy in both directions you know that.
Revolutionary KRM-II-81 New Hope:
KRM-II-81 Drug-Resistant Epilepsy Patients
https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/
National Institutes of Health
A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/
Jodi L. Smith, PhD, MD, FAANS, Director, Pediatric Neurosurgery at Peyton Manning Children’s Hospital at Ascension St. Vincent Medical in Indianapolis, IN led this research effort and is quoted as saying, “I am happy to report that a year after the surgery the patient is seizure-free but remains on seizure medication. Although our research team has observed suppression of activity previously in cortical tissue from epileptic patients, we have now observed recurrent epileptiform bursting in this patient’s tissue. KRM-II-81 fully suppressed the epileptiform bursting, which returned when KRM-II-81 was removed from the incubation medium. We feel that this observation is an impressive indicator for success in translation to patient treatment for this compound.”
Jodi L. Smith, MD, is a pediatric neurosurgeon at Peyton Manning Children's Hospital at Ascension St. Vincent Pediatric Neurosurgery in Indianapolis, Indiana.
Dr. Jodi L. Smith is an academic pediatric neurosurgeon at James Whitcomb Riley Hospital for Children and an Associate Professor of Neurological Surgery in the Department of Neurological Surgery at the Indiana University Medical Center/Indiana University School of Medicine in Indianapolis, Indiana.
Dr. Smith received her Ph.D. in Anatomy at the University of Utah School of Medicine for her doctoral dissertation studies on "Neurulation." Dr. Smith subsequently completed medical school and residency training in Neurological Surgery at the University of Utah, as well. Following residency, Dr. Smith completed a pediatric neurosurgery fellowship at Children's Hospital, Harvard Medical School in Boston, Massachussetts. Dr. Smith joined the Department of Neurological Surgery at the Indiana University Medical Center/Indiana University School of Medicine in Indianapolis, Indiana in 2000.
Dr. Smith is a Diplomat of the American Board of Neurological Surgery, and her memberships include The Congress of Neurological Surgeons, The American Association of Neurological Surgeons, The American Association of Neurological Surgeons - Pediatric Section, and The Society for Neuroscience.
Dr. Smith is the founder and Co-director of the pediatric surgical epilepsy program at Riley Hospital for Children, Indiana University School of Medicine. Her responsibilities include (1) evaluating pediatric patients with medically refractory epilepsy to determine whether they qualify for surgical treatment of their seizures; and (2) operating on all children with medically refractory epilepsy who are found to be appropriate surgical candidates in order to rid them of their debilitating seizures.
Specialties: Dr. Smith's clinical interests include pediatric epilepsy surgery, brain and spinal cord tumors, brain and spinal cord congenital malformations, hydrocephalus, myelodsyplasia, craniofacial disorders, and Moyamoya syndrome. Dr. Smith's research interests include understanding the cellular and molecular mechanisms of neurulation and understanding the electrophysiological properties of dysplastic/epileptogenic human cortical tissue using a multi channel electrode array.
The manuscript’s corresponding author Rok Cerne, MD, PhD, Senior Research Fellow with RepireRx, said that “the bursting activity across a neural network is a unique signature of epilepsy that we were able to observe in the cortical tissue from this patient. Prior to surgery, this 19-year-old patient suffered from seizures in the presence of multiple standard anti-seizure medications. The complete abolishment of these epileptic bursts by our GABAkine is one of most impressive demonstrations we have made to date with KRM-II-81. The data are highly encouraging for us to continue with IND enabling animal studies conducted in collaboration with the National Institutes of Health and to move into the clinic with KRM-II-81.”
https://www.otcmarkets.com/stock/RSPI/news/story?e&id=2731514
Rok Cerne, MD, PhD, Senior Research Fellow with RepireRx
Rok Cerne. Principal Research Scientist at Eli Lilly and Company. Eli Lilly and Company Iowa State University. Indianapolis, Indiana, United States.
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
ResolutionRx: Pharmaceutical Cannabinoids.
ResolutionRx Ltd (Australian Company Number a/k/a ACN 664 925 651) was formed in Australia on January 11, 2023 by RespireRx as an unlisted public company. RespireRx has contributed by sublicense and license with ResolutionRx, its sleep apnea drug development program subject to certain liabilities. ResolutionRx now engages in the research and development (“R&D”) associated with that program, initially for the development of a new formulation of dronabinol for use in a Phase 3 clinical trial and the filing for regulatory approval for the treatment of obstructive sleep apnea (“OSA”). The current total budget for that program over the next several years is approximately US$16.5 million, most, but not all of which is expected to be eligible for the Australian R&D Tax Incentive (“RDTI”). Dronabinol, an endocannabinoid receptor agonist, has already demonstrated significant improvement in the symptoms of OSA in two Phase 2 clinical trials. OSA is a serious respiratory disorder that impacts an estimated 90 million people in the United States, the United Kingdom, Germany and Australia and that has been linked to increased risk for hypertension, heart failure, depression, and diabetes. There are no approved drug treatments for OSA.
Because dronabinol is already FDA approved for the treatment of AIDS related anorexia and chemotherapy induced nausea and vomiting, RespireRx and ResolutionRx further believe that its repurposing strategy would only require, in the United States, approval by the FDA of a 505(b)(2) new drug application (“NDA”), an efficient regulatory pathway that allows the use of publicly available data.
on January 18, 2024, the Board of Directors of RespireRx Pharmaceuticals Inc. appointed a new director, Dariusz Nasiek to the Board who is considered to be an outside director.
Dr. Nasiek, MD, MBA, is a dedicated anesthesiologist with expertise in anesthesiology and interventional pain management. Dr. Nasiek is board certified by the American Board of Anesthesiology, the American Board of Pain Medicine and the American Board of Interventional Pain Physicians. Dr. Nasiek is also a Life Member of the American Society of Interventional Pain Physicians and a Member of the International Spine Intervention Society. He has been a practicing physician for the last 35 years. Since 2006, he has been the Managing Partner of Allied Neurology & Interventional Pain Practice, and since 2008, he has served as the Director of Anesthesiology at Hackensack Surgery Center. Dr. Nasiek is a leader specializing in non-surgical options for the treatment of spinal and non-spinal pain and is a pioneer in the use of innovative techniques in the cervical, thoracic and lumbar spine. His forward-looking approaches to pain management, regenerative medicine and tissue healing are described in the new 2nd Edition of his book entitled, “PRP, Platelet Rich Plasma: A New Paradigm in Regenerative Medicine.”
RespireRX Gabakine KRM-II-81
KRM-II-81 is the lead compound in a new series of orally bioavailable imidazodiazepines entering IND-enabling safety studies.
KRM-II-81 has a preclinical profile predicting efficacy against pharmacoresistant epilepsies, traumatic brain injury, and neuropathic pain.
KRM-II-81 is the most advanced and druggable of a series of compounds that display certain receptor subtype selectivity and pharmacological specificity. In studies using cell cultures, brain tissues and whole animals, KRM-II-81 acts as a GABAA PAM at selective GABAA receptor subtypes that we feel are intimately involved in neuronal processes underlying epilepsy, pain, anxiety and certain other indications.
KRM-II-81 has demonstrated highly desirable properties in animal models of these and other potential therapeutic indications, in the absence of or with greatly reduced liability to produce sedation, motor incoordination, cognitive impairments, respiratory depression, tolerance, abuse and withdrawal seizures, all side effects associated with BDZs. We currently are focused on the potential treatment of epilepsy and pain.
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.sciencedirect.com/science/article/pii/S2405844023109601
Dampening effects of KRM–II–81 on epileptiform bursting in a slice of left temporal lobe focal brain tissue resected from the patient. Data were collected for 1 h under control conditions (Control), in the presence of 30 µM KRM–II–81 (KRM–II–81 (30 µM)), and after the wash out of KRM–II–81 (Wash).
B. Summary data for the epileptiform burst activity under 1 h control, KRM–II–81, and wash out conditions. KRM–II–81 completely suppressed epileptic bursting activity in the slice.
KRM-II-81 is an imidazodiazepine anticonvulsant that has shown promising results in preclinical studies. Here are some key findings:
• KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment-resistant and pharmaco-resistant models.
• It has been effective across a broad array of anti-seizure models including those predicting efficacy in patients that are pharmaco-resistant and in brain tissue from epilepsy patients who are no longer treatable with drugs.
• Notably, KRM-II-81 was found to be highly effective in these models, and pharmaco-resistance or tolerance did not develop to its anti-convulsant properties.
• In addition to its anti-convulsant properties, KRM-II-81 has also shown to be effective in relieving acute, chronic, and neuropathic pain in a number of models without developing tolerance or producing sedation.
• KRM-II-81 has also displayed a high degree of analgesic activity in a broad range of preclinical studies.
These results suggest that KRM-II-81 could potentially be a promising candidate for the treatment of epilepsy and chronic pain.
KRM-II-81 has shown some promising results when compared to other anticonvulsants. Here are some key points:
• KRM-II-81 is more potent and generally more efficacious than standard-of-care antiepileptics.
• In multiple chemical seizure provocation models in mice, KRM-II-81 was either equally or more efficacious than that of Diazepam (DZP). Most strikingly, KRM-II-81 but not DZP blocked the development of seizure sensitivity to the chemical convulsants cocaine and pentylenetetrazol.
• KRM-II-81 produces broad-based anticonvulsant and antinociceptive efficacy in rodent models and provides a wider margin over motoric side effects than that of other GABAA receptor PAMs
KRM-II-81 has been studied in preclinical trials and so far, it has not displayed side effects such as sedation and motor impairment.
Importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability.
However, these are preclinical findings, and further research, including clinical trials in humans, would be necessary to fully understand its safety profile. Always consult with a healthcare professional before starting any new medication.
The global epilepsy drug market size varies according to different sources:
• According to Mordor Intelligence, the epilepsy drugs market is projected to register a CAGR of 3.5% during the forecast period.
• Grand View Research reported that the global epilepsy drugs market size was valued at USD 10.15 billion in 2022 and is expected to grow at a CAGR of 5.1% from 2023 to 2030.
• Allied Market Research valued the global epilepsy drugs market size at $7 billion in 2022, and projected it to reach $9.8 billion by 2032, growing at a CAGR of 3.5% from 2023 to 2032.
• Fortune Business Insights reported that the global antiepileptic drugs (AED) market size was valued at USD 15.55 billion in 2022, and is projected to grow from USD 16.50 billion in 2023 to USD 22.37 billion by 2030, exhibiting a CAGR of 4.4% during the forecast period.
• The Brainy Insights reported that the global epilepsy drugs market was valued at USD 10 billion in 2022 and grew at a CAGR of 4% from 2023 to 2032. The market is expected to reach USD 14.80 billion by 2032.
RespireRX has been accepted into the NIH HEAL Initiative® NINDS Preclinical Screening Platform for Pain (PSPP) program. The company’s lead GABAkine, KRM-II-81, is being developed because of its ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects.
On August 3, 2023, RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd, its wholly-owned, unlisted, public Australian subsidiary entered into a License Agreement pursuant to which, RespireRx has licensed to ResolutionRx, the Intellectual Property which includes the Patent Rights. The License is an exclusive, worldwide and royalty-free license during the Term to use and exploit the Licensed IP in connection with ResolutionRx’s business and operations, including commercial and non-commercial purposes, with the exception that RespireRx shall have the exclusive right to use the technology described in the Licensed IP for non-cannabinoid products. ResolutionRx shall use its best efforts to commercialize the Licensed IP.
The Licensed IP is basically, the intellectual property and patent rights, and associated with the new dronabinol formulation initially to be developed for the treatment of obstructive sleep apnea.
On October 9, 2023, ResolutionRx Ltd a wholly owned Australian, public, unlisted subsidiary of RespireRx Pharmaceuticals Inc. entered into a Master Services Agreement with Ab Initio Pharma Pty Ltd, an Australian company for Ab Initio to manufacture, formulate, test and supply ResolutionRx with therapeutic drugs based on lipid nanoparticle technology licensed from RespireRx to ResolutionRx.
The initial services relate to ResolutionRx’s repurposing of dronabinol and its development program for obstructive sleep apnea pursuant to which Ab Initio will, among other things, manufacture and test our new dronabinol lipid nanoparticle formulation for pharmacokinetic, pharmacodynamic, and pivotal clinical trials as well as ultimately for commercialization.
On December 6, 2023, RespireRx Pharmaceuticals Inc. entered into an agreement with Ponto Ventures LLC, pursuant to which Ponto will provide the services of Will Clodfelter. Clodfelter will be retained by the Company as our Senior Vice President of Business Development. Also on December 6, 2023, the Company entered into an agreement with Seven Life Sciences related to the introduction of Ponto and Consultant to the Company.
Consulting Agreement
Pursuant to the terms of the Consulting Agreement, the parties agreed that Clodfelter will be retained by the Company as the Senior Vice President of Business Development through Ponto on a part-time basis.
Consultant’s duties will be such duties as are normally associated with the position of Senior Vice President of Business Development, working as an independent contractor and not as an employee, with an initial focus on the programs of ResolutionRx Ltd, the Company’s wholly-owned Australian subsidiary. Consultant will collaborate with Jeff Eliot Margolis, the Company’s Senior Vice President, Chief Financial Officer, Treasurer and Secretary and together, both will periodically submit the results of their efforts to Dr. Arnold Lippa, the Interim Chief Executive Officer, Interim President and Chief Scientific Officer of the Company.
Consultant will in all ways, satisfy the requirements of being an independent contractor.
In the event Clodfelter is involved in any substantive way in the successful consummation of a strategic transaction resulting in cash proceeds to the Company or one of its subsidiaries, the Company on behalf of itself or the appropriate subsidiary shall create a success bonus pool calculated on a tiered formula calculated on all funds, in the aggregate, received with respect to such transaction, upfront or in milestone payments once received. For clarity, royalties, profit participation or similar funds received will not be funds utilized in the calculation of the bonus. Since all funds may not be received at one time, to determine the “tier” the funds that are received shall be aggregated with funds previously received.
Dronabinol is marketed as Marinol and Syndros, a registered trademark of Solvay Pharmaceuticals.
Dronabinol is also marketed, sold, and distributed by PAR Pharmaceutical Companies under the terms of a license and distribution agreement with SVC pharma LP, an affiliate of Rhodes Technologies for Marinol and Insys Pharmaceuticals for Syndros.
RespireRx
RespireRx is developing a pipeline of new drug products based on our broad patent portfolios for two drug platforms, including dronabinol (D-9THC), and the ampakines, which positively modulate AMPA-type glutamate receptors to promote neuronal function.
RespireRx holds the exclusive world-wide license to a broad family of patents for the use of cannabinoids in the treatment of sleep related breathing disorders from the University of Illinois at Chicago (UIC). There are six issued patents, and we have several extensions and pending applications that will extend patent protection for over a decade.
Under the terms of the license agreement, RespireRx now holds the exclusive rights to develop and commercialize dronabinol for sleep related breathing disorders. The use of dronabinol for the treatment of OSA is a new indication for an already approved drug, thereby allowing RespireRx or a development partner to submit a 505(b)2 application to FDA for approval of a new dronabinol label. This regulatory path may offer market protections under HatchWaxman provisions for market exclusivity at FDA. Other regulatory routes are available to pursue proprietary formulations of dronabinol that will provide further market protections.
Obstructive sleep apnea syndrome (OSA) is a sleep-related breathing disorder that afflicts an estimated 29 million people in the United States and over 100 million people worldwide.
Average cost to treat a patient with OSA is approximately $2,100 per year.
Dronabinol is a Schedule III, controlled generic drug that has been approved by the U.S. FDA for the treatment of AIDS-related anorexia and chemotherapy-induced emesis. Dronabinol is available in the United States as the branded prescription drug product Marinol® capsules. Marinol®, together with numerous generic formulations, is available in 2.5, 5, and 10 mg capsules, with a maximum labelled dosage of 20 mg/day for the AIDS indication, or 15 mg/m2 per dose for chemotherapy-induced emesis.
Marinol
What is the cost of Marinol
Marinol prices
Oral Capsule
2.5 mgMarinol oral capsule
from $740.72for 60 capsules
5 mgMarinol oral capsule
from $1,531.40for 60 capsules
The cost for Marinol oral capsule 2.5 mg is around $741 for a supply of 60 capsules, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
A generic version of Marinol is available. See dronabinol prices (from $94.16 for 60 capsules).
Syndros
Syndros (dronabinol) is a member of the miscellaneous antiemetics drug class and is commonly used for AIDS Related Wasting, Anorexia, and Nausea/Vomiting - Chemotherapy Induced.
The cost for Syndros oral solution (5 mg/mL) is around $1,227 for a supply of 30 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
https://www.pharmacychecker.com/syndros/#!
Syndros is available as a brand name drug only, a generic version is not yet available.
RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development
Mr. Clodfelter will initially lead the business development efforts with respect to dronabinol, the lead asset of ResolutionRx Ltd, a wholly-owned Australian subsidiary of the Company. Mr. Clodfelter will collaborate with Jeff Eliot Margolis, the Company’s Senior Vice President
Mr. Clodfelter has extensive experience providing business development, strategy, and valuation consulting services to pharmaceutical, biotech and medical device companies, where he has led or been a core member on over 30 international and domestic pharmaceutical licensing and device negotiations ranging from preclinical to launched products. This experience extends across large pharmaceutical, biotechnology and medical device companies. He previously held positions at Eli Lilly and Co. in Corporate Strategy and Business Development. He was at Amylin Pharmaceuticals in New Product Planning and Decision Sciences and was involved in multiple business development activities. Following Amylin, Mr. Clodfelter was the Chief Executive Officer of Medicus Biosciences and Abvance Therapeutics, both biotechnology firms based in California.
Will Clodfelter
Managing DirectorManaging Director
Ponto Ventures, LLC
Linkedin 4,028 followers
Business Development | Biotech Leadership and Startup | Corporate Strategy | Medical Devices | Pharmaceuticals | CEO | CBO
Biotech executive with extensive experience in developing and implementing corporate strategy, managing complex relationships and cross-cultural teams, and monetizing ideas for startup biotech ventures. Recognized for ability to distill complex scientific and engineering principles and translate into actionable, market-based business strategies. Managed P&L for startup and established firms. Core member on over 30 international and domestic licensing and device negotiations ranging from pre-clinical to launched products.
Key strengths include: business development, corporate and asset strategy, device development, alliance management, negotiations, licensing, financial valuations, forecasting, market research, new product planning
$RSPI
KRM-II-81 New Hope
https://investorshub.advfn.com/uimage/uploads/2024/2/9/fmidjKRM1.jpg
Drug Companies making Epilepsy medication
MRNS $10.08
CERE $43.16
STOK $4.98
UCBJF $102.00
SNY $45.63
PFE $27.00
OTSUK $18.36
RespireRx Pharmaceuticals Ticker: RSPI
Is working on Revolutionary New Hope:
KRM-II-81 Drug-Resistant Epilepsy Patients
Link found on National Library of Medicine
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders
https://pubmed.ncbi.nlm.nih.gov/35041859/
https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/
National Institutes of Health
A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/
Bullish
Recent RSPI News
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
